CD28 and cancer: Next, we determined by the same methodology whether tTregs costimulated via TNFR2 or CD28 gain features of Tregs described in diseased human tissues, using published Treg gene signatures from cancer and autoimmune diseases (Supplemental Table 2) (39, 41, 52–60).